"The rise in Market Size is due to an increasing incident population of Multiple Myeloma patients in the 6MM, along with expected entry of premium price asset which will have an impact on market size"

LAS VEGAS, April 8, 2020 /PRNewswire/ -- DelveInsight has announced an addition of a new market research report on "CAR T-Cell Therapy for Multiple Myeloma Market Insights and Market Forecast-2030" to its offerings.

The report offers in-depth CAR T-Cell Therapy for Multiple Myeloma Market Analysis, 11 years Market Size Forecast, detailed Epidemiology analysis and 11-year Forecast, Emerging Drugs Market Uptake and information related to Leading Companies along with the Competitive Analysis edge.

Some key highlights from the report

:

Click here to getCAR T-Cell Therapy for Multiple Myelomamarket sample pages: https://delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-market

Chimeric Antigen Receptor (CAR) T-cell therapy is a technique that involves genetic modification of patient's autologous T-cells for CAR expression, specific for a tumor antigen, followed by ex-vivo cell expansion and re-infusion back to the patient.

Chimeric Antigen Receptor T-cells are the fusion proteins of a selected single-chain fragment that are the variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. T-cell genetic modification may occur either through viral-based gene transfer methods or non-viral methods like DNA-based transposons, CRISPR/Cas9 technology, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), or direct transfer of in vitro transcribed-mRNA by electroporation.

CAR T-Cell Therapy for Multiple Myeloma Treatment Market

According to WHO, in the year 2018, 159,985 incident cases of multiple myeloma were reported in the world. Multiple myeloma is a rare type of cancer that develops in plasma cells. The patients diagnosed with Multiple Myeloma have cancer cells that eventually supersede the healthy plasma cells. This process exhausts the much-needed white blood cells in the body.

A cure for Multiple Myeloma currently is not available. However, significant research is making progressive leaps toward a Multiple Myeloma treatment that eliminates the disease entirely. Some of them are enumerated below:

Targeted therapy: Targeted drug treatment targets on specific abnormalities within cancer cells that enables them to survive. The drugs like Bortezomib (Velcade), carfilzomib (Kyprolis) and ixazomib (Ninlaro), which may be administered through a vein in the arm or in pill form, block the action of a substance in myeloma cells that breaks down proteins. Eventually, it leads to the myeloma cells to die.

Biological therapy: Biological therapy drugs use body's immune system to kill myeloma cells. The drugs like thalidomide (Thalomid), lenalidomide (Revlimid) and pomalidomide (Pomalyst) improve the immune system cells to identify and fight cancer cells. These medications are usually taken in pill form.

Chemotherapy: Chemotherapy drugs kill fast-growing cells like myeloma cells. Chemotherapy drugs can be administered through a vein in the arm or taken in pill form.

Corticosteroids: Prednisone and dexamethasone regulate the immune system to control inflammation in the body. They are also active against myeloma cells. Corticosteroids can be taken in pill form or administered through a vein in patient's arm.

Story continues

Radiation therapy: This treatment uses beams of energy, such as X-rays and protons, to kill myeloma cells and prohibit their growth. Radiation therapy may be used to swiftly shrink myeloma cells in a specific area.

Several biotechnological companies that are working towards the development of therapies and will impact CAR T-Cell Therapy for Multiple Myeloma treatment market scenario in the upcoming years.

Drugs covered in the report are:-

And many others

TheCAR T-Cell Therapy for Multiple Myeloma Market Key Players are:-

And many others

Scope of the report:

Click here to getCAR T-Cell Therapy for Multiple Myelomamarket sample pages: https://delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-market

Insight covered regarding Reimbursement Scenario in Multiple Myeloma CAR T-Cell Therapy

Approaching reimbursement can have a positive influence on both during the late stages of product development and after product launch. In report, reimbursement is taken into consideration to identify economically attractive indications and market opportunities. When working with limited resources, the ability to choose the markets with the fewest reimbursement barriers can be a critical business & price strategy.

KOL- Views

To keep up with current market trends, KOLs and SME's opinions, working in CAR T-Cell Therapy for Multiple Myeloma domain are taken into account through primary research to fill the data gaps and validate the secondary research. Their opinion assist to comprehend and validate current and emerging therapies treatment patterns and Multiple Myeloma market trend. This will benefit the clients in potential upcoming novel CAR T-Cell Therapy for Multiple Myeloma treatment by recognizing the overall scenario of the market and the unmet needs.

Click here to getCAR T-Cell Therapy for Multiple Myelomamarket trends sample pages: https://delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-market

Reasons to buy

Key Topics Covered:

1

Key Insights

2

Executive Summary

3

CAR T-Cell Therapy Market Overview at a Glance

4

CAR T-Cell Therapy Background and Overview

5

CAR T-Cell Therapy for Multiple Myeloma (MM): 6 Major Market Analysis

6

CAR T-Cell Therapy Market Outlook

7

CAR T-Cell Therapy Emerging Drug Profiles for Multiple Myeloma

7.1

bb2121: Celgene Corporation

7.2

JNJ-68284528 (LCAR-B38M): Janssen Research & Development

7.3

P-BCMA-101: Poseida Therapeutics

7.4

CAR-CD44v6: MolMed S.p.A.

7.5

JCARH125 (Orvacabtagene autoleucel): Celgene Corporation

7.6

Descartes-08: Cartesian Therapeutics

7.7

CT053 : CARsgen Therapeutics)

7.8

PBCAR269A: Precision BioSciences

8

United States Market Size

9

EU-5 Market Size

9.1

Germany

9.2

France

9.3

Italy

9.4

Spain

9.5

United Kingdom

10

CAR T-Cell Therapy Clinical Trials in 6MM

11

KOL Views CAR T-Cell Therapy

12

CAR T-Cell Therapy for Multiple Myeloma Market Drivers

13

CAR T-Cell Therapy for Multiple Myeloma Market Barriers

14

Appendix

15

DelveInsight Capabilities

16

Disclaimer

17

About DelveInsight

Request a Webex Demo to get a walk-through of the report: https://delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Related Reports:-

DelveInsight's "CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) Market Insights and Market Forecast- 2030" report delivers an in-depth understanding of the CAR T-Cell Therapy use for Acute Lymphoblastic Leukemia as well as the CAR T-Cell Therapy market trends for Acute Lymphoblastic Leukemia in the 6MM i.e., United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).

DelveInsight's 'CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market Insights and Market Forecast-2030' report delivers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma and market trends in the 6MM, i.e., United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

Contact us:Shruti Thakurinfo@delveinsight.com+91-9650213330DelveInsight

View original content:http://www.prnewswire.com/news-releases/market-size-of-car-t-cell-therapy-for-multiple-myeloma-in-the-6mm-is-expected-to-be-usd-3-766-4-million-in-2030--some-of-the-major-players-involved-are-celgene-corporation-janssen-research--development-poseida-therapeutics-m-301037648.html

View post:
Market Size of CAR T-Cell Therapy for Multiple Myeloma in the 6MM is Expected to Be USD 3,766.4 Million in 2030 | Some of the Major Players Involved...

Comments are closed.